My Cart [ 0 ]
Home > Cell Biology > Stable Cell Lines > Rituxan Biosimilar Stable Cell Line

Rituxan Biosimilar Stable Cell Line

Rituximab, Anti-CD20 Chimeric Monoclonal Antibody

Catalog No. Product Name Size List Price (US$) Quantity
C010 Rituxan Biosimilar Stable Cell Line 1 package Request

B-lymphocyte antigen CD20 encoded by the MS4A1 gene is an activated-glycosylated phosphoprotein on the surface of all B-cells. The function of the membrane protein is to stimulate B-cell immune response, specifically against T-independent antigens though its natural ligand remains unknown. CD20 is important for the development and differentiation of B-cells into plasma cells. CD20 belongs to the membrane-spanning 4A family with common structural features, similar intron/exon splice boundaries, and unique expression patterns among hematopoietic cells and nonlymphoid tissues.

Rituximab (trade names Rituxan and MabThera), a chimeric anti-CD20 monoclonal antibody, destroys B cells and is used to treat diseases with excessive numbers of B cells, overactive B cells, or dysfunctional B cells, such as many lymphomas, leukemias, transplant rejection, and autoimmune disorders.

C010: Rituxan Biosimilar Stable Cell Line (CHO)

The yield of Rituxan biosimilar from the CHO stable cell line was above 1.8 g/L in a 3 liter manufacturing.

The stable cell line alone can be transfered alone or together with the technology of process development and/or antibody purification.

Related Links

See our Privacy Policy